Sensitization of glioma cells to fas-dependent apoptosis by chemotherapy-induced oxidative stress

Cancer Research

Volumn 65, Issue 12, 2005, Pages 5248-5255

  Xia, Shuli ^a   Rosen, Eliot M ^b   Laterra, John ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLLEUCYLGLUTAMINYLHISTIDYLASPARTYL FLUOROMETHYL KETONE; CAMPTOTHECIN; CASPASE 3; CASPASE 8; CASPASE 9; CH 11; CYSTEINE PROTEINASE INHIBITOR; DOXORUBICIN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; GLUTATHIONE; HYDROGEN PEROXIDE; LIPOCORTIN 5; LYMPHOCYTE ANTIGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ANTIBODY; PROTEIN KINASE B; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SECRETION; RECEPTOR UPREGULATION; WESTERN BLOTTING;

ANTIBODIES; ANTIGENS, CD95; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; OXIDATIVE STRESS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 20444454275     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4332     Document Type: Article

References (50)

1. Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003;98:71-108.
2. Roth W. Weller M. Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives. Cell Mol Life Sci 1999;56:481-506.
3. Weller M, Rieger J, Grimmel C, et al. Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 1998;79:640-4.
4. Weller M, Kleihues P, Dichgans J, Ohgaki H. CD95 ligand: lethal weapon against malignant glioma? Brain Pathol 1998;8:285-93.
5. Choi C, Benveniste EN. Fas ligand/Fas system in the brain; regulator of immune and apoptotic responses. Brain Res Brain Res Rev 2004;44:65-81.
6. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003;15:983-92.
7. Chinnaiyan AM, Tepper CG, Seldin MF, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-5.
8. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8.
9. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254:439-59.
10. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001;202122-33.
11. Gross A, Yin XM, Wang K, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999;274:1156-63.
12. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
13. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481-90.
14. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001;3:535-46.
15. Petak I, Houghton JA. Shared pathways: death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol Res 2001;7:95-106.
16. Ozoren N, El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-47.
17. Tachibana O, Nakazawa H, Lampe J, Watanabe K, Kleihues P, Ohgaki H. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res 1995;55:5528-30.
18. Frankel B, Longo SL, Leach C, Canute GW, Ryken TC. Apoptosis and survival in high-grade astrocytomas as related to tumor Fas (APO-1/CD95) expression. J Neurooncol 2002:59:27-34.
19. Strege RJ, Godt C, Stark AM, Hugo HH, Mehdorn HM. Protein expression of Fas, Fas ligand, Bcl-2 and TGFβ2 and correlation with survival in initial and recurrent human gliomas. J Neurooncol 2004;67:29-39.
20. Husain N, Chiocca EA, Rainov N, Louis DN, Zervas NT. Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines. Acta Neuropathol (Berl) 1998;95:287-90.
21. Riffkin CD, Gray AZ, Hawkins CJ, Chow CW, Ashley DM. Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. Neuro-oncol 2001;3:229-40.
22. Frankel B, Longo SL, Kyle M, Canute GW, Ryken TC. Tumor Fas (APO-1/CD95) up-regulation results in increased apoptosis and survival times for rats with intracranial malignant gliomas. Neurosurgery 2001;49:168-75.
23. Yoon G, Kim KO, Lee J, et al. Ceramide increases Fas-mediated apoptosis in glioblastoma cells through FLIP down-regulation. J Neurooncol 2002;60:135-41.
24. Choi C, Xu X, Oh JW, et al. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase. Cancer Res 2001;61:3084-91.
25. Yount GL, Levine KS, Kuriyama H, Haas-Kogan DA, Israel MA. Fas (APO-1/CD95) signaling pathway is intact in radioresistant human glioma cells. Cancer Res 1999;59:1362-5.
26. Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N. c-Jun NH2-terminal kinase-dependent Fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 2003;55:265-80.
27. Mansouri A, Ridgway LD, Korapati AL, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003;278:19245-56.
28. Murakata C, Kaneko M, Gessner G, et al. Mixed lineage kinase activity of indolocarbazole analogues. Bioorg Med Chem Lett 2002;2:147-50.
29. Kwon D, Choi C, Lee J, et al. Hydrogen peroxide triggers the expression of Fas/FasL in astrocytoma cell lines and augments apoptosis. J Neuroimmunol 2001;113:1-9.
30. Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P. p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int J Biochem Cell Biol 2002;34:148-57.
31. Devadas S, Hinshaw JA, Zaritskaya L, Williams MS. Fas-stimulated generation of reactive oxygen species or exogenous oxidative stress sensitize cells to Fas-mediated apoptosis. Free Radic Biol Med 2003;35:648-61.
32. Eichhorst ST, Muller M, Li-Weber M, Schulze-Bergkamen H, Angel P, Krammer PH. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 2000;20:7826-37.
33. Stendel R, Scheurer L, Stoltenburg-Didinger G, Brock M, Mohler H. Enhancement of Fas-ligand-mediated programmed cell death by taurolidine. Anticancer Res 2003;23:2309-14.
34. Ciusani E, Perego P, Carenini N, et al. Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors. Biochem Pharmacol 2002;63:881-7.
35. Ferreira CG, Span SW, Peters GJ, Kruyt FA, Giaccone G. Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 2000;60:7133-41.
36. Kim JH, Ajaz M, Lokshin A, Lee YJ. Role of antiapoptotic proteins in tumor necrosis factor-related apoptosis-inducing ligand and cisplatin-augmented apoptosis. Clin Cancer Res 2003;9:3134-41.
37. Schiffer D, Ferracini R, Cavalla P. Heterogeneity of apoptotic pathways and c.Jun/JNK expression in malignant gliomas. Anticancer Res 2001;21:2531-5.
38. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J, Weller M. Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 1997;44:55-63.
39. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999;274:7987-92.
40. Micheau O, Hammann A, Solary E, Dimanche-Boitrel MT. STAT-1-independent up-regulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem Biophys Res Commun 1999;256:603-7.
41. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-α, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res 2004;298:560-73.
42. Franzoso G, Zazzeroni F, Papa S. JNK: a killer on a transcriptional leash. Cell Death Differ 2003;10:13-5.
43. Mielke K, Herdegen T. JNK and p38 stress kinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 2000;61:45-60.
44. Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anti-Canc Agents 2003;3:271-90.
45. Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. Br J Cancer 2000;82:1827-34.
46. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxid Redox Signal 2002;4:405-14.
47. Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004;44:239-67.
48. Cardoso SM, Rego AC, Penacho N, Oliveira CR. Apoptotic cell death induced by hydrogen peroxide in NT2 parental and mitochondrial DNA depleted cells. Neurochem Int 2004;45:693-8.
49. Tews DS. Cell death and oxidative stress in gliomas. Neuropathol Appl Neurobiol 1999;25:272-84.
50. Takuma K, Baba A, Matsuda T. Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 2004;72:111-27.